Methenamine hippurate EQL Pharma approved
Methenamine hippurate EQL Pharma is a pharmaceutical that is taken as a prophylaxis against recurrent urinary tract infections.
Methenamine hippurate EQL Pharma contains methenamine, a substance that has been registered in Sweden since 1973. Methenamine hippurate EQL Pharma becomes the first and only generic available on the markets where it is registered. The market for methenamine 1g tablet is medium sized in the countries concerned with about 35.5 MSEK in total annual sales, of which about half is in the UK
The product is expected to be launched during the fourth quarter, 2019.